<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541109</url>
  </required_header>
  <id_info>
    <org_study_id>Persian Polypill</org_study_id>
    <nct_id>NCT03541109</nct_id>
  </id_info>
  <brief_title>A Polypill for Secondary Prevention of Ischemic Heart Disease</brief_title>
  <official_title>Adherence to and Cost-effectiveness of a Polypill Versus Usual Care for Secondary Prevention of Cardiovascular Diseases in Patients With a History of Acute Coronary Syndrome in Isfahan, Iran, a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. The
      most important aspect of CVD secondary prevention is adherence to guideline-indicated
      pharmacological therapy which globally remains low. In previous studies, a Polypill
      containing fixed dose combination of essential drugs have improved patient adherence to these
      drugs. The effect of such a strategy on pharmacological therapy uptake, cost-effectiveness,
      and CVD recurrence in our setting will be assessed in this study. Participants hospitalized
      in three referral hospitals in Isfahan, Iran because of an acute coronary syndrome (ACS) or
      revascularization procedure (PCI or CABG) will be randomized to either receiving Polypill or
      four components of Polypill separately. Patient recruitment will be carried out at the time
      of patient discharge from the hospitals.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient adherence to Aspirin at the final visit</measure>
    <time_frame>34 months</time_frame>
    <description>patient is adherent if achieves a score of more than 6 from validated Persian version of Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8) (score: 0 to 8) and more than 85% of pills prescribed over last 3 months are consumed (pill count method)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient adherence to Atorvastatin at the final visit</measure>
    <time_frame>34 months</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient adherence to Metoprolol at the final visit</measure>
    <time_frame>34 months</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient adherence to valsartan at the final visit</measure>
    <time_frame>34 months</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient adherence to Aspirin, Atorvastatin, Metoprolol, Valsartan</measure>
    <time_frame>1 month</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient adherence to Aspirin, Atorvastatin, Metoprolol, Valsartan</measure>
    <time_frame>4 months</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient adherence to Aspirin, Atorvastatin, Metoprolol, Valsartan</measure>
    <time_frame>10 months</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient adherence to Aspirin, Atorvastatin, Metoprolol, Valsartan</measure>
    <time_frame>22 months</time_frame>
    <description>MMAS-8 questionnaire and pill count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness of Polypill treatment compared with four drugs administered separately</measure>
    <time_frame>up to 34 months</time_frame>
    <description>The analysis will be done on direct and indirect costs of treatment. Direct costs will be assessed from perspective of health care system. Current Iranian public medical tariffs will be the base of calculations. The incremental cost effectiveness ratio (ICER) will be calculated for primary outcomes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>drug related adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>assessed by a questionnaire filled by the responsible physician</description>
  </other_outcome>
  <other_outcome>
    <measure>drug related adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>assessed by a questionnaire filled by the responsible physician</description>
  </other_outcome>
  <other_outcome>
    <measure>drug related adverse events</measure>
    <time_frame>10 months</time_frame>
    <description>assessed by a questionnaire filled by the responsible physician</description>
  </other_outcome>
  <other_outcome>
    <measure>drug related adverse events</measure>
    <time_frame>22 months</time_frame>
    <description>assessed by a questionnaire filled by the responsible physician</description>
  </other_outcome>
  <other_outcome>
    <measure>drug related adverse events</measure>
    <time_frame>34 months</time_frame>
    <description>assessed by a questionnaire filled by the responsible physician</description>
  </other_outcome>
  <other_outcome>
    <measure>patient satisfaction with drug consumption</measure>
    <time_frame>1 month</time_frame>
    <description>Satisfaction Questionnaire for Medication (TSQM)</description>
  </other_outcome>
  <other_outcome>
    <measure>patient satisfaction with drug consumption</measure>
    <time_frame>4 months</time_frame>
    <description>Satisfaction Questionnaire for Medication (TSQM)</description>
  </other_outcome>
  <other_outcome>
    <measure>patient satisfaction with drug consumption</measure>
    <time_frame>10 months</time_frame>
    <description>Satisfaction Questionnaire for Medication (TSQM)</description>
  </other_outcome>
  <other_outcome>
    <measure>patient satisfaction with drug consumption</measure>
    <time_frame>22 months</time_frame>
    <description>Satisfaction Questionnaire for Medication (TSQM)</description>
  </other_outcome>
  <other_outcome>
    <measure>patient satisfaction with drug consumption</measure>
    <time_frame>34 months</time_frame>
    <description>Satisfaction Questionnaire for Medication (TSQM)</description>
  </other_outcome>
  <other_outcome>
    <measure>health related quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>Validated Persian version of the EuroQol-5D (EQ-5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>health related quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>Validated Persian version of the EuroQol-5D (EQ-5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>health related quality of life</measure>
    <time_frame>10 months</time_frame>
    <description>Validated Persian version of the EuroQol-5D (EQ-5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>health related quality of life</measure>
    <time_frame>22 months</time_frame>
    <description>Validated Persian version of the EuroQol-5D (EQ-5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>health related quality of life</measure>
    <time_frame>34 months</time_frame>
    <description>Validated Persian version of the EuroQol-5D (EQ-5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>major adverse cardiovascular events</measure>
    <time_frame>from time of randomization up to 34 months</time_frame>
    <description>Including ACS, re-hospitalization, revascularization, heart failure, stroke, and CVD mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in systolic blood pressure from baseline</measure>
    <time_frame>baseline and 1 month</time_frame>
    <description>average readings of systolic blood pressure measured two times (at least 3 min apart) at sitting position</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in systolic blood pressure from baseline</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>average readings of systolic blood pressure measured two times (at least 3 min apart) at sitting position</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in systolic blood pressure from baseline</measure>
    <time_frame>baseline and 10 months</time_frame>
    <description>average readings of systolic blood pressure measured two times (at least 3 min apart) at sitting position</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in systolic blood pressure from baseline</measure>
    <time_frame>baseline and 22 months</time_frame>
    <description>average readings of systolic blood pressure measured two times (at least 3 min apart) at sitting position</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in systolic blood pressure from baseline</measure>
    <time_frame>baseline and 34 months</time_frame>
    <description>average readings of systolic blood pressure measured two times (at least 3 min apart) at sitting position</description>
  </other_outcome>
  <other_outcome>
    <measure>change in serum LDL from baseline</measure>
    <time_frame>baseline and 1 month</time_frame>
    <description>fasting Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>change in serum LDL from baseline</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>fasting Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>change in serum LDL from baseline</measure>
    <time_frame>baseline and 10 months</time_frame>
    <description>fasting Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>change in serum LDL from baseline</measure>
    <time_frame>baseline and 22 months</time_frame>
    <description>fasting Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>change in serum LDL from baseline</measure>
    <time_frame>baseline and 34 months</time_frame>
    <description>fasting Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Revascularization</condition>
  <arm_group>
    <arm_group_label>Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polypill available in two forms of tablets with fixed dose combinations of Aspirin (80mg), Atorvastatin (40mg), Metoprolol (50 mg), and Valsartan (40 mg or 80 mg), prescribed once daily by moth for 34 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four drugs prescribed separately including Aspirin (80mg), Atorvastatin (40mg), Metoprolol (50 mg), and Valsartan (40 mg or 80 mg), once daily by moth for 34 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polypill</intervention_name>
    <description>Polypill tablet</description>
    <arm_group_label>Polypill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin tablet</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin tablet</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol tablet</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Metoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan tablet</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients hospitalized in the mentioned hospitals because of an acute coronary syndrome
             or revascularization procedure (PCI or CABG)

          -  signing informed concent

          -  clear indication of receiving all components of Polypill (aspirin, statin, ACE
             inhibitor/ARB, and beta blocker)

          -  living in Isfahan city or nearby areas so that they can attend follow-ups

          -  No mental illness limiting their self-care ability or Severe illness with an estimated
             lifespan of less than 3 years

          -  No history of adverse reaction or contraindication to any component of the Polypill

          -  Not having Secondary hyperlipidemia, serum creatinine â‰¥ 2, severe heart failure

          -  No plan for a procedure (CABG, PCI, or another surgical procedures) within following 6
             months

        Exclusion Criteria:

          -  Patient unlikely to complete trial

          -  Need to change or discontinue any of the four principal drugs of the Polypill to
             achieve better control of the disease or risk factors or because of adverse drug
             reactions (based on physician's idea)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masoumeh Sadeghi, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masoumeh Sadeghi, Professor</last_name>
    <phone>00989134091776</phone>
    <email>sadeghimasoumeh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shervin Ghaffari Hoseini, MD,PhD</last_name>
    <email>shghaffari@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Research Institute</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Safoora yazdekhasti</last_name>
      <phone>00983136115208</phone>
      <email>sfa.yazdekhasti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nizal Sarrafzadegan, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shervin Gh Hoseini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hamidreza Roohafza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjan Mansourian, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamshid Najafian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alireza Nateghi Nateghi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Masoumeh Sadeghi</investigator_full_name>
    <investigator_title>Head of Cardiac Rehabilitation Research Center</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>fixed dose combination therapy</keyword>
  <keyword>cost effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year after study completion</ipd_time_frame>
    <ipd_access_criteria>Requests will be assessed by a responsible panel after signing a data access agrement.</ipd_access_criteria>
    <ipd_url>http://icri.mui.ac.ir/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

